Dosage Forms

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Pfizer announced this his week that it had entered into a strategic global agreement for the worldwide commercialization with the Indian biotechnology company Biocon (Bangalore) for biosimilar versions of insulin and insulin analog products (e.g., recombinant human insulin, glargine, aspart, and lispro).

Pfizer Takes Biosimilars Plunge

FDA to Hold Public Hearing on Biosimilars Legislation, And More.

Regulatory Roundup: FDA to Hold Public Hearing on Biosimilars Legislation, And More.

The generic-drug company Actavis (Hafnarfjordur, Iceland) is considering acquiring a 51% stake in the biopharmaceutical company BioPartners Holdings (Barr, Switzerland) from Bioton, a Polish biotechnology company.

Actavis Signals Interest in Biosimilars Market

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Director General of the European Generic Medicines Association (EGA), Greg Perry, has emphasised the need for EU biosimilar guidelines for monoclonal antibodies (mAbs), as well as a harmonised, global approach to biosimilars in general, at the agency's 8th International Symposium on Biosimilar Medicines.

Call for "workable" guideline for biosimilar mAbs

Director General of the European Generic Medicines Association (EGA), Greg Perry, has emphasized the need for EU biosimilar guidelines for monoclonal antibodies (mAbs), as well as a harmonized, global approach to biosimilars in general, at the agency's 8th International Symposium on Biosimilar Medicines.

Call for "Workable" Guideline for Biosimilar mAbs

A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.

A SWOT Analysis Of The Biosimilars Market

Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.

Clinical and cost considerations of developing a biosimilar

Ameet Malik is Global Head, Sandoz Biopharmaceuticals.

In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.

Biosimilars: Perception, cost And The Impact On Biotech Innovation

Paul Greenland is Biosimilars Marketing Director for Europe, Middle East and Africa at Hospira.

Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.

Launching And Commercializing Biosimilars

Keith Watson is a Principal Consultant at PAREXEL Consulting.

Cecil Nick is Vice President, Biotechnology, at PAREXEL Consulting.

Bruce Babbitt is a Principal Consultant, PAREXEL Consulting

Generic Drugs